OMEROmeros Corporation
Omeros Corporation, a clinical-stage biopharmaceutical company, discovers, develops, and commercializes small-molecule and protein therapeutics, and orphan indications targeting immunologic diseases. The company's lead p…
Industry Peers
Biotechnology| Headline | Source | Time |
|---|---|---|
Older | ||
 Omeros (OMER) Q2 2026 Earnings Call Transcript Yartemlia generated $32.2M in gross sales during its first full quarter on market. | ||
 Omeros (OMER) Turns Profitable As Investors Ask If The Repricing Has Gone Too Far Omeros (OMER) stock is reacting to a clear shift in its financial story after the company reported second quarter 2026 results that moved from a prior net loss to positive net income. See our latest analysis for Omeros. The latest move to a closing share price of $17.35 comes after a sharp re-rating, with a 30-day share price return of 65.24% and a 1-year total shareholder return of 321.12%. This suggests momentum has accelerated following Omeros' earnings and buyback updates. If you are... | ||
 This Biotech Stock Just Gapped Up To A Five-Year High; Here's Why Omeros stock rocketed to a five-year high Thursday on blowout second-quarter results for its new treatment for transplant complications. | ||
 Omeros Corporation Q2 2026 Earnings Call Summary Moby summary of Omeros Corporation's Q2 2026 earnings call | ||
 Omeros Q2 Earnings Call Highlights Omeros (NASDAQ:OMER) reported second-quarter net sales of $28.5 million for YARTEMLEA, its newly launched treatment for hematopoietic stem cell transplant-associated thrombotic microangiopathy, or TA-TMA, as the company generated positive operating cash flow and reduced its convertible debt after th | ||
 Omeros (OMER) Q2 Earnings and Revenues Beat Estimates Omeros (OMER) delivered earnings and revenue surprises of +107.41% and +130.07%, respectively, for the quarter ended June 2026. Do the numbers hold clues to what lies ahead for the stock? | ||
 OMER Stock Soars 24% After-Hours On YARTEMLEA Sales Momentum, Debt Reduction And Share Buybacks Gross revenues from YARTEMLEA reached $32.2 million in the quarter, nearly triple the $11.1 million recorded in the first quarter. | ||
OMER Stock Gains 4% — CMS Green-Lights $287K Add-On Payments For Transplant Drug Starting October 1, hospitals can receive up to about $287,000 more from Medicare for each qualifying patient for Yartemlea, Omeros said. | ||
AstraZeneca's Rare Disease Setback Is A 'Clear Positive' For Omeros, Says This Analyst – A Look At Some Key Highlights H.C. Wainwright reiterated its ‘Buy’ rating on Omeros after AstraZeneca's Phase 3 setback in HSCT-TMA, saying that the outcome improves Yartemlea's competitive positioning. | ||
 Omeros (OMER) is Amongst The Best Names Under $10 That Could Yield More Than 200% Return Omeros Corp. (NASDAQ:OMER) is one of the 10 best stocks under $10 that could triple. On June 26, Omeros Corp. (NASDAQ:OMER) released an update regarding the Committee for Medicinal Products for Human Use’s (CHMP) review of a marketing authorization application for the company’s narsoplimab. This antibody targets MASP-2 to cure hematopoietic stem cell transplant-related thrombotic […] | IInsider Monkey | |
IInsider Monkey | ||